Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Actavis to sell generic Celebrex
After a court ruling yesterday, Pfizer's (NYSE:PFE) fourth best-selling drug Celebrex may now come off of patent protection as early as this May, although Pfizer (NYSE:PFE) will appeal the ruling. And Actavis (NYSE:AGN) plans on being among the first to offer a generic version of the megablockbuster painkiller. Although Celebrex saw sales of approximately $3 billion last year, generic manufacturers, like Actavis (NYSE:AGN), will face stiff competition. Specifically, five companies have already been identified as players in the race to manufacture generic Celebrex. So, although Actavis (NYSE:AGN) will certainly benefit from the court's decision to invalidate a patent that would have extended the drug's patent protection until 2016, it's hard to see how any one company will necessarily be gaining a lion's share of the generic Celebrex pie. As such, I don't think this news will be a major event for Actavis (NYSE:AGN) moving forward.
DepoMed continues to rally after earnings?
Shares of DepoMed (NASDAQ:DEPO) are up over 6% in premarket this morning after management provided some color on the company's stronger than expected fourth quarter earnings report. Specifically, DepoMed (NASDAQ:DEPO) crushed the Street's estimates yesterday for both earnings and revenue. Revenue beat estimates by over 100% and earnings per share beat by 27%.
Although better than expected sales of Gralise and Zipsor contributed to the beat, the bulk of it can be attributed to a deal with PDL Biopharma (NASDAQ:PDLI) for future royalty and milestone payments in the company's diabetes franchise. Per the terms of the deal, DepoMed (NASDAQ:DEPO) received $240.5 million in exchange for interests in future royalty and milestone payments in the Type 2 diabetes therapeutic area. DepoMed (NASDAQ:DEPO) recognized $18.1 million of non-cash revenues and $4.5 million in non-cash interest expense under this arrangement in the fourth quarter.
What really stands out in this earnings report, however, is the company's strong 2014 guidance. Namely, DepoMed (NASDAQ:DEPO) expects total revenues to increase by over 400% this year, mostly due to the deal with PDL Biopharma (NASDAQ:PDLI). So, there is good reason to keep tabs on DepoMed going forward.
Horizon beats on revenue but misses on earnings
Shares of Horizon Pharma (NASDAQ:HZNP) are down almost 5% in premarket this morning after the company missed revenue estimates by $2.08 million, or 6%. The company did beat on earnings by $0.04 due to the early termination of a senior loan facility in the fourth quarter related to the acquisition of Vimovo from AstraZeneca.
What investors are keying in on this morning are sales of Horizon's (NASDAQ:HZNP) flagship arthritis drug Duexis. Despite gross sales growing by 548% year over year, analysts expected slightly higher revenue in the fourth quarter. A closer look at the press release shows that this lower revenue from Duexis sales is tied to service fees paid to wholesale distributors in the quarter, which were higher than anticipated.
Looking ahead, Horizon (NASDAQ:HZNP) is expected to grow net revenue by a notable 80% to 100% in 2014, thereby achieving profitability on a non-GAAP basis. So, even though Horizon (NASDAQ:HZNP) shares are up 510% in the past year, there is good reason to believe this stock could continue to climb even higher. As such, you might want to dig deeper into this rising biopharma.
Today's movers in biotech may have great potential, but they may have trouble keeping up with this top stock.
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.